Intelligent Bio Solutions: Drug testing with a listing-compliance clock.

Executive Summary

Intelligent Bio Solutions, Inc. (Nasdaq: INBS) is a New York–headquartered medical-technology company commercializing a non-invasive fingerprint sweat drug-screening platform — a portable handheld reader paired with single-use cartridges that returns results in under ten minutes. The company reports 480-plus active customer accounts across 27 countries and more than 1,700 installed readers.

Fiscal first-half 2026 revenue was $2.01 million, up 36% year over year, with gross margins expanding to 49% from 39%.

Two facts coexist. On one side, operating momentum is genuinely improving: reader sales doubled year over year in the second quarter, customer additions accelerated, and a manufacturing partnership with Syrma Johari is projected to deliver greater than 40% annual production cost savings. On the other, the company executed a 1-for-10 reverse stock split in December 2025 to address a Nasdaq minimum-bid-price deficiency — and is operating under an initial 180-day compliance window that expires June 15, 2026. The FDA 510(k) clearance pathway that would unlock U.S. market entry is in motion but is not under the company's direct timing control.

Business Overview

INBS commercializes the Intelligent Fingerprinting Drug Screening System, a portable two-part platform designed for workplace and safety-sensitive drug testing. The donor places the fingertip on the cartridge collection area for five seconds; the cartridge is inserted into the digital reader; the reader returns results in under ten minutes. The system screens for amphetamines (including methamphetamine and MDMA), cocaine, cannabis, and opiates (including the heroin-specific metabolite 6-MAM). A rapid-cartridge variant targeting 70% faster results entered validation testing in April 2026.

The product economics follow a razor-and-razorblade structure: reader hardware sales are followed by recurring single-use cartridge revenue. In fiscal Q2 2026 (quarter ended December 31, 2025), reader sales of $246,519 grew 104% year over year, while cartridge sales of $516,754 grew approximately 33%.

A second product, the SmarTest Sweat Drug Testing Patch, is a wearable 7-to-10-day continuous-monitoring device distributed under a global agreement. SmarTest covers a broader panel than the fingerprint system — adding fentanyl, methadone, buprenorphine, hydrocodone, oxycodone, benzodiazepines, barbiturates, and phencyclidine to the four core classes — and targets continuous-monitoring applications such as corrections, court-mandated rehabilitation, and probation.

Customer Base and Markets

The April 2026 deck displays a customer roster that includes UK transportation operators (Eastern Airways, P&O Ferries, Abellio), industrial and construction firms (Princebuild, Hill, Hegarty, McCann, MASTERSON Holdings, A&F Sprinklers), packaging and logistics firms (Smurfit Westrock, Palletways, Boughey), and stevedoring operators (Precision Stevedores, RMS Ports).

Customer testimonials describe two operational outcomes: process efficiency gains and behavioral effects. A&F Sprinklers states the program reduced non-negative test results by approximately 90% across its sites; Precision Stevedores cites a 12- to 18-month ROI payback versus prior urine-testing costs.

Method	Detection Window	Test Time	Annual Cost (80 tests)
Fingerprint (INBS)	16–24 hours	Under 10 min	~$5,500
Saliva	Up to 2 days	Up to 20 min	~$7,600
Urine	Up to 4 days	20 min – 4 hrs	~$7,750

Financial Performance

Metric	Q2 FY2026	YoY	H1 FY2026	YoY
Revenue	$896,774	+48%	$2.01M	+36%
Reader Sales	$246,519	+104%	—	—
Cartridge Sales	$516,754	+33%	—	+38%
Gross Margin	—	—	49%	+10 pts

Despite the year-over-year improvement, absolute revenue remains small relative to the company's market capitalization and operating losses. A trailing-twelve-months net loss of approximately $2.26 million was reported on TTM revenue near $741,000 (the TTM figure trails the fiscal H1 figure due to reporting-period timing).

Capital Structure

INBS executed a 1-for-10 reverse stock split effective at 11:59 p.m. Eastern Time on December 15, 2025, reducing common shares issued and outstanding to approximately 959,533 immediately following the split. The action followed Nasdaq's December 15, 2025 deficiency notice — the closing bid price had been below $1.00 for 30 consecutive trading days, breaching Listing Rule 5550(a)(2). Nasdaq granted an initial 180-day compliance period, ending June 15, 2026.

On January 2, 2026, the company closed a $10.0 million private placement priced at-the-market under Nasdaq rules, with net proceeds of approximately $9.4 million. Per the April 2026 investor deck, common stock issued as of March 31, 2026 was 2,001,173 shares, with pre-funded warrants of 1,642,425 — implying total common equivalent shares of 3,643,598.

The stock closed at $2.45 on April 29, 2026, per Robinhood data, against a 52-week range of $2.31 to $24.90. Market capitalization at that close was approximately $4.84 million.

FDA Pathway and U.S. Market Entry

The April 2026 deck reports that the company is pursuing FDA 510(k) clearance for the Intelligent Fingerprinting Drug Screening System, initially anchored on detection of the opiate codeine. Clearance is described as enabling expansion beyond Forensic Use Only settings into the U.S. drug-screening market, which the deck cites at $3.5 billion in 2024 — approximately 27.8% of the global drug-screening market.

The reported study sequence:

• FDA Cut-Off and Penetration studies — complete as of the April 2026 deck.
• Method Comparison study — expected June 2026.
• Interference study — expected July 2026.
• Codeine Screening Clinical Program — launched January 28, 2026.

The company anticipates FDA 510(k) clearance in the second half of 2026.

Recent Developments

• December 12–15, 2025 — Filed Certificate of Amendment for 1-for-10 reverse split; received Nasdaq minimum-bid-price deficiency notice.
• December 31, 2025 — Announced manufacturing partnership with Syrma Johari Medtech.
• January 2, 2026 — Closed $10.0 million private placement.
• January 28, 2026 — Launched Codeine Screening Clinical Program; initiated additional FDA 510(k) studies.
• February 12, 2026 — Reported record fiscal Q2 revenue growth of 48% YoY with reader sales surging 104% YoY.
• February 24–25, 2026 — Announced partnership with Bouygues UK, a subsidiary of multi-billion-dollar Bouygues Construction, for an initial 13-site UK drug-testing rollout.
• April 17–20, 2026 — Completed penetration testing; announced launch of validation study for rapid-cartridge variant targeting 70% faster results.

Stated Investment Thesis

Management's case rests on three pillars. First, the platform's detection-window advantage: 16 to 24 hours, compared with up to two days for saliva and up to four days for urine — making fingerprint testing better suited to "fitness-for-duty" assessment rather than retrospective use. Second, the operational advantage: rapid sample collection, batch testing in 2–3 minutes per batch, no specialized staff or biohazardous-disposal infrastructure required, and lower average annual cost than urine or saliva at typical workplace volumes. Third, the market-entry catalyst: FDA 510(k) clearance to unlock U.S. workplace, healthcare, and government markets representing 27.8% of the global drug-screening total addressable market.

Risks

• Listing compliance. Nasdaq minimum-bid-price compliance window expires June 15, 2026. Failure to regain compliance could trigger further listing actions, though the company may be eligible for an additional 180-day period under specified conditions.
• FDA timing. 510(k) clearance for codeine is anticipated by management in the second half of 2026 but is not within company control. Method Comparison and Interference studies remain outstanding.
• Revenue scale. Absolute revenue remains small relative to operating losses. Continued operating-cash-flow burn requires either revenue inflection or additional capital.
• Dilution. Substantial warrant overhang relative to current common-equivalent shares; multiple capital raises in the prior 18 months have produced cumulative dilution.
• Geographic concentration. Customer base is predominantly outside the United States. U.S. market entry is the central growth catalyst but is unproven.
• Competitive landscape. Established urine- and saliva-based testing modalities are entrenched in workplace and government procurement processes.
• Forensic Use Only restriction. Current U.S. activity is limited to Forensic Use Only settings pending FDA clearance, capping the addressable U.S. market.

Conclusion

INBS presents a cleaner operating-momentum profile than is typical for a sub-$10 million-market-cap company: 36% H1 revenue growth, 49% gross margins, 1,700-plus installed readers, named multinational customers, and a credible FDA clearance pathway that — if delivered on management's stated timeline — would open a multi-billion-dollar U.S. addressable market. The same period saw a defensive reverse split and an at-the-market financing, illustrating the gap between operating progress and the public market's tolerance for cash burn at this scale.

Three events in the next six months will substantially clarify the investment case: the June 15, 2026 Nasdaq compliance deadline; the Method Comparison and Interference studies expected in June and July 2026; and any FDA 510(k) clearance disclosure in the second half of 2026.

Key Takeaways

• INBS commercializes a non-invasive fingerprint sweat drug-screening platform with 480-plus active accounts across 27 countries and 1,700-plus installed readers.
• Fiscal H1 2026 revenue was $2.01 million, up 36% YoY; Q2 revenue grew 48% YoY with reader sales up 104% YoY. Gross margins expanded to 49% from 39%.
• The company executed a 1-for-10 reverse stock split on December 15, 2025 and is operating under a Nasdaq minimum-bid-price compliance window ending June 15, 2026.
• FDA 510(k) clearance for codeine is the principal U.S. market-entry catalyst, anticipated by management in the second half of 2026.
• A manufacturing partnership with Syrma Johari Medtech is projected to deliver greater than 40% annual production cost savings; first readers under the partnership shipped February 2026.

Sources: Intelligent Bio Solutions — Investor Presentation, April 2026; INBS SEC filings including Form 10-Q for fiscal Q2 2026 and reverse-split-related Form 8-K filings; GlobeNewswire releases (December 2025 – April 2026); Stock Titan; The Markets Daily; Simply Wall St; Yahoo Finance; Robinhood; Stock Analysis; CNBC; Nasdaq.com.